The Impact of PCSK9 Modulation on Cardiovascular Outcomes: Recent Advances and the Managed Care Implications
To claim CE credit for this activity, please visit ABSTRACT http://www.pharmacytimes.org/pcsk9-ajmc Am J Manag Care. 2022;28(suppl 8):S139-S147. https://doi.org/10.37765/ajmc.2022.89269 Introduction to Hypercholesterolemia: Epidemiology and the Burden of Disease Cardiovascular disease (CVD)...
Conclusions/Relevance: Managed care professionals have considerable experience with developing approaches to providing access to novel injectable lipid-lowering therapies, such as alirocumab and evolocumab, and with the approval of inclisiran, they now have an expanding list of such therapies to incorporate into their care plans.
Share
Bempedoic acid, an ATP citrate lyase inhibitor, reduces intimal hyperplasia via activation of AMPKα signaling pathway
Source : https://www.sciencedirect.com/science/article/pii/S1567576922008761?via=ihub
* ACLY was firstly demonstrated to be significantly increased in PDGF-BB induced dedifferentiated smooth muscle cells. * * Bempedoic acid significantly reduced ACLY expression and inhibited VSMC dedifferentiation in the...
/>
Conclusions: We demonstrates that bempedoic acid reduces ACLY expression to restrain VSMC proliferation and dedifferentiation by activating AMPK/ACC signaling pathway, which may provide a potential therapeutic strategy for diseases associated with intimal hyperplasia including restenosis and atherosclerosis.
Share
PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and their Future Perspectives
Source : https://www.eurekaselect.com/article/127987
Cardiovascular disorders (CVDs) are the leading cause of death worldwide and are accelerated via the low level of low-density lipoprotein-cholesterol (LDL-C). The proprotein convertase subtilis/kexin type9 (PCSK9), a vital regulator...
Relevance: This review plays a pivotal role for the researchers and scientists working on PCSK9 inhibitors to treat cardiovascular disorders.
Share
Effect of blood lipids and lipid-lowering therapies on osteoarthritis risk: A Mendelian randomization study
Source : https://www.frontiersin.org/articles/10.3389/fmed.2022.990569/full
BackgroundWe aimed to investigate the effects of blood lipids and lipid-lowering agents on osteoarthritis (OA) risk.Materials and methodsWe performed Mendelian randomization (MR) analyses to estimate the causal effect of blood...
Conclusions: The findings suggested that LDL-C increments have independent protective effects on both knee and hip OA. LDL-C-lowering effects of statins may increase the risk of knee OA.
Share
Safety of PCSK9 inhibitors
Source : https://www.sciencedirect.com/science/article/pii/S0753332222013464?via=ihub
PCSK9 inhibitors do not affect the increase in new cases of diabetes. * Treatment with PCSK9 inhibitors has a lower risk of muscle side effects. * PCSK9 inhibitors do not...
/>
Relevance: The purpose of this review is to summarize information on the safety profile of PCSK9 inhibitors, which may help in making therapeutic decision.
Share